蕈样肉芽肿患者第二恶性肿瘤的筛查
本研究基于SEER-18数据库742例蕈样肉芽肿(MF)合并第二恶性肿瘤患者,描述其多为白人男性、MF诊断时平均年龄55-67岁、第二肿瘤诊断时61-72岁且多数MF为早期。MF合并NHL、肺癌、膀胱癌者第二肿瘤分期更早、5年总生存更好,而黑色素瘤无此优势;作者建议定期淋巴结和色素性皮损检查、戒烟及常规癌症筛查。
要点
- MF患者第二肿瘤多为白人男性,多数MF诊断时为早期。
- MF合并NHL、肺癌、膀胱癌者第二肿瘤分期更早且5年总生存更好。
- MF合并黑色素瘤者分期和生存较无MF者无改善,需定期色素性皮损检查。
核心结论
- MF患者发生NHL、肺癌、膀胱癌时第二肿瘤分期更早且5年总生存更好,而黑色素瘤无此优势。
研究设计与样本
- 基于SEER-18数据库识别742例MF合并第二恶性肿瘤患者进行特征描述。
主要发现
- 第二肿瘤患者多为白人男性,MF诊断时平均年龄55-67岁,第二肿瘤诊断时平均年龄61-72岁。
- 多数第二肿瘤患者的MF为早期。
- MF合并NHL、肺癌、膀胱癌者第二肿瘤分期更早且5年总生存更好。
- MF合并黑色素瘤者分期和生存较无MF者无改善。
临床怎么用
- 定期进行淋巴结检查和以色素性皮损为重点的皮肤检查。
- 详细询问系统回顾问题,进行戒烟咨询。
- 确保年龄和性别特异性癌症筛查(如肺癌筛查、乳腺X线摄影、结肠镜检查)及时更新。
- 定期影像学检查和实验室检查(如尿常规)用于第二肿瘤筛查的效用尚需研究和专家共识。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with mycosis fungoides (MF) are at increased risk of developing non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), lung cancer, bladder cancer and melanoma. The characteristics of patients developing these malignancies have not been specifically delineated. In addition, there are no established guidelines for screening MF patients for second malignancies. MATERIALS/METHODS: We identified 742 patients with MF who developed second malignancies in the Surveillance Epidemiology and End Result-18 database. RESULTS: The majority of second malignancy patients were white and male, mean age 55-67 years at diagnosis of MF, and mean age 61-72 years at diagnosis of second malignancy. The majority of patients diagnosed with second malignancies had early stage MF. MF patients with NHL, lung cancer, and bladder cancer tended to be diagnosed at earlier stages of the second malignancy than patients without MF and demonstrated better 5-year overall survival. There was no improvement in stage at diagnosis or survival for MF patients who were diagnosed with melanoma compared to patients without MF. CONCLUSIONS: Improvements in survival in MF/NHL, MF/lung cancer and MF/bladder cancer patients may reflect differences in disease biology secondary to having MF or the importance of increased contact with the healthcare system. MF/melanoma data suggest that patients require regular pigmented-lesion-focused skin examinations. Tools for screening include regular lymph node examinations, pigmented-lesion-focused examinations and detailed review of systems questions. Smoking cessation counseling is key intervention in this population, as is ensuring that all age- and sex-specific cancer screenings are up-to-date (e.g. lung cancer screening, mammography, and colonoscopy). The utility of regular imaging for second malignancy screening and lab testing such as routine urinalysis requires additional study and expert consensus.
引用
- Goyal A, O'Leary D, Goyal K, et al. Screening for second malignancies in mycosis fungoides: non-Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer and melanoma. J Eur Acad Dermatol Venereol. 2021. PMID: 34013554. doi:10.1111/jdv.17384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。